Thursday, November 30, 2023 |
Mostly Cloudy

Emergent BioSolutions closes acquisition of smallpox drug from Chimerix

September 29, 2022

Gaithersburg’s Emergent BioSolutions Inc. (NYSE: EBS) has completed its acquisition of a smallpox drug, four months after striking the deal — and paving another path for the local company to bolster the national stockpile. Emergent said this week it closed its agreement with Durham, North Carolina’s Chimerix Inc. (NASDAQ: CMRX) for exclusive worldwide rights to Tembexa, the first treatment for smallpox greenlit by the Food and Drug Administration.

Article Source: Baltimore Business Journal

The Morning Rundown

We’re staying up to the minute on the issues shaping the future. Join us on the newsletter of choice for Maryland politicos and business leaders. It’s always free to join and never a hassle to leave. See you on the inside.